Today: 16 June 2026
Browse Category

NASDAQ:AGIO 19 November 2025

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals’ Phase 3 RISE UP trial of mitapivat in sickle cell disease met its hemoglobin-response primary endpoint but failed to show a significant reduction in pain crises or fatigue. Shares fell sharply, dropping as much as 50% pre-market before paring losses. The company plans to meet with the FDA in early 2026 to discuss a potential U.S. marketing application.
19 November 2025
··

Stock Market Today

  • Del Monte Director Ahmad Abu-Ghazaleh Purchases 4,000 Shares at $29.41
    June 15, 2026, 7:37 PM EDT. Ahmad Abu-Ghazaleh, a director at Del Monte Corp (FDP), acquired 4,000 shares on June 11, 2026, at a price of $29.4054 per share. This transaction increased his direct ownership to 54,000 shares, including shares held by his spouse and children. The filing was reported through a SEC Form 4, which discloses changes in beneficial ownership by insiders such as directors or officers. The purchase reflects a notable insider activity ahead, potentially signaling confidence in the company's outlook.

Latest articles

HUB Cyber Security Surges 42% Following Filings, Nasdaq Status Update

HUB Cyber Security Surges 42% Following Filings, Nasdaq Status Update

16 June 2026
HUB Cyber Security shares soared 42% to $1.68 with after-hours quotes at $1.86 on heavy volume, driven by momentum from recent ownership filings and a 1-for-20 reverse split, not new operating news; the next key catalyst is HUB’s overdue 2025 Form 20-F and Nasdaq compliance plan, due July 17, with delisting risk if not resolved.
Nokia falls as AI trade cools, investors eye July update

Nokia falls as AI trade cools, investors eye July update

16 June 2026
Nokia shares fell 3.32% in Helsinki despite a record-setting European market, as investors paused after a 74% three-month surge fueled by AI optimism; with the stock now trading above most analyst targets, all eyes turn to the July 23 Q2 results for proof that rapid gains are justified.
Go toTop